Gandhi Happy Cat Study Notes
Gandhi Happy Cat Study: Reduced Anticoagulation Dose
Introduction
The Gandhi Happy Cat study, published in the New England Journal of Medicine, aimed to evaluate the possibility of using a reduced dose of anticoagulation in cancer patients who experienced a venous thromboembolic event (VTE) after an initial 6-month treatment with a therapeutic dose.
Duration of Anticoagulant Treatment
Despite accumulated data, the optimal duration of anticoagulant treatment remains a partially unresolved issue. Key considerations include:
VTE Favored by Major Event (e.g., Surgery): Low recurrence risk (1-3% at 5 years) justifies shorter anticoagulation, typically 3 months.
Idiopathic VTE: Higher recurrence risk (10% at 1 year, 30% at 5 years) necessitates longer anticoagulation.
Cancer-Associated VTE: Highest recurrence risk (around 20% after 1 year if anticoagulation is stopped), often requiring long-term anticoagulation until cancer remission.
ESC Guidelines for VTE Events
The European Society of Cardiology (ESC) classifies VTE events based on the annual recurrence risk upon anticoagulation cessation:
Low Risk (Green): VTE associated with surgery, hospitalization, or trauma with fracture; short anticoagulation durations are sufficient.
High Risk (Red): Cancer patients require long-term anticoagulation until cancer remission.
Reduced Dose Studies in Idiopathic VTE
AMPLIFY-EXT: Demonstrated the non-inferiority of reduced-dose apixaban (2.5 mg twice daily) compared to therapeutic dose (5 mg twice daily) after 6 months of therapeutic anticoagulation for idiopathic VTE. Showed a trend towards fewer bleeding complications.
EINSTEIN CHOICE: Rivaroxaban (10 mg) was superior to aspirin (100 mg) in preventing VTE recurrence, with similar bleeding risk. This study compared rivaroxaban 20mg vs 10mg vs aspirin.
These studies support the recommendation of reduced-dose anticoagulants for idiopathic VTE in international guidelines (Grade A recommendation).
Challenges in Treating Cancer-Associated VTE
Treating VTE in cancer patients is challenging because:
Higher VTE recurrence rate (2-3 times) compared to non-cancer patients.
Increased bleeding complications (2-3 times) despite therapeutic anticoagulation.
Therefore, reducing bleeding complications by decreasing the anticoagulant dose would be highly beneficial.
Apixaban for the Treatment of Cancer Associated Thrombosis (APICAT) Study Design
The APICAT study was a multicenter, randomized, double-blind, non-inferiority trial. Patients with cancer and acute VTE were anticoagulated for at least 6 months with a therapeutic anticoagulant. Then, they were randomized to receive either:
Apixaban 5 mg twice daily (therapeutic dose)
Apixaban 2.5 mg twice daily (prophylactic dose)
The treatment duration was 12 months. The primary outcome was VTE recurrence, and the safety outcome was major bleeding or clinically relevant non-major bleeding (CRNMB). The non-inferiority margin was set at 2 for the hazard ratio.
Inclusion Criteria
All cancer types were eligible, except limited cutaneous cancers and primary brain tumors or tumors with intracerebral metastases.
VTE events included deep vein thrombosis (DVT) or pulmonary embolism (PE). Distal DVT and subsegmental PE were excluded.
Patients had to have received at least 6 months of therapeutic anticoagulation.
Patient Characteristics
Mean age: 67 years.
VTE presentation: 75% with PE, 25% with DVT only.
Cancer stage: 66% with metastatic cancer.
Common cancer types: breast, colorectal, lung, prostate. Over 50% had other cancer locations including thrombogenic cancers like pancreatic and gallbladder cancers.
APICAT Study Results
Primary Outcome (VTE Recurrence): 2.8% in the apixaban 5 mg arm vs. 2.1% in the apixaban 2.5 mg arm. The upper bound of the hazard ratio confidence interval was 1.41, which was below the non-inferiority margin of 2. Demonstrating non-inferiority of the reduced dose.
Safety Outcome (Major Bleeding/CRNMB): 15.6% in the apixaban 5 mg arm vs. 12.1% in the apixaban 2.5 mg arm. Demonstrated superiority for the reduced dose.
Major Bleeding Alone: No statistically significant difference.
APICAT Study Conclusion
Reduced-dose apixaban (2.5 mg twice daily) was non-inferior to full-dose apixaban (5 mg twice daily) for preventing VTE recurrence in cancer patients. It also decreased the incidence of clinically important bleeding complications. The study duration was one year, so longer-term benefits are unknown, but likely to persist.
Integration with Other Studies
The RENOVA study, published in The Lancet, had a similar design to APICAT but included patients with idiopathic VTE. Patients were anticoagulated for 6-24 months and then randomized to reduced or full-dose apixaban or rivaroxaban. The follow-up duration was 5 years.
*RENOVA Results: 2.2% VTE recurrence in the reduced-dose arm vs. 0.8% in the full-dose arm. The non-inferiority margin was 1.7, but the upper bound of the hazard ratio confidence interval was 2.6. Non-inferiority was not statistically demonstrated, however rates of VTE recurrence were very low at 2.2% after 5 years.
RENOVA Bleeding Complications Clinically relevant bleeding: 9.9% vs 15%. Major bleeding: 2.1% vs 4%. A large reduction in major bleeding was observed, 60%.
Overall Conclusions
Even though non-inferiority was not reached in the RENOVA study, the data suggests that reduced-dose anticoagulation is a good option. The RENOVA and APICAT studies support that reduced-dose anticoagulation is a valid option for both idiopathic and cancer-associated VTE.
Question from Audience
Is 2.5 mg apixaban once daily an option? No data exists to support this. The 2.5 mg twice daily dose is used for prophylaxis after orthopedic surgery. Phase 2 studies with 1-2 mg apixaban showed increased VTE events. This is unsupported and unlikely to be effective.